Disruptive drugs against Neuropathic pain

An estimated 10% of the western population suffers from chronic neuropathic pain. Current drugs are hampered by limited effectiveness and central nervous system side effects.

Like many breakthroughs in the history of medicine, relief of neuropathic pain after treatment with an EGFR-inhibitor was a serendipitous discovery.  

More about AKIGAI's story
The EGFR ReceptorThe EGFR Receptor

The EGFR is one of the most studied molecules in the human body.

The science behind AKIGAI's approach

AKIGAI is a biotech-startup whose founders hold global use patents for a drug class that has been given to millions of people for over 20 years.

The two routes of administration

AKIGAI's approach is twofold. We envision two paths to development of a new type of EGFR-inhibitor.

Learn about AKIGAI's strategy
2. Tablets for chronic pain 1. Intravenous drug for time- limited pain

Collaborate with AKIGAI

AKIGAI is looking for partners and collaborators to help realize EGFR-inhibitors for use against neuropathic pain.

More about collaborations

We are proud to be
working with

Sørlandet Sykehus

Møsbu AS